33. The Ozempic Trade: "Health" and Body Imag...

Send us Fan Mail Mindy Kaling's new sitcom "Not Suitable for Work" just dropped, and we have thoughts. We are two Wall Street veterans breaking down everything the show gets right — and wrong — about what it actually looks like to show up as a first-year analyst at a bulge bracke ...  Show more

Send us Fan Mail While everyone's been fixated on the SpaceX IPO, Google quietly pulled off the largest equity offering in history—roughly $85 billion—and basically front-ran the entire market to do it. In this episode of The Skinny on Wall Street, Kristen and Jen break down why ...  Show more

Episode 601: Sam Parr ( https://twitter.com/theSamParr ) and Shaan Puri ( https://twitter.com/ShaanVP ) talk to Calley Means ( https://x.com/calleymeans ) about the $50T drug that has Americans in a chokehold.  — Show Notes: (0:00) Intro  (1:54) The problem with Ozempic (4:25) A ...  Show more

Let's dive into the rise of GLP-1 medications and what they mean for both the body and the mind. From Serena Williams stepping in as the face of Ro’s GLP-1 campaign, to Kyla’s personal weight loss journey, we explore the intersections of medicine, celebrity culture, and lived exp ...  Show more

First there was Weight Watchers, then there was Noom, and now there’s…Wegovy? Bloomberg health reporter Emma Court helps us understand the evolution of dieting programs and where they’re going next. Later, Matthew Schnier of New York Magazine and The Cut walks us through his arti ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more